Squarepoint
AQST icon

Squarepoint’s Aquestive Therapeutics AQST Stock Holding History

Squarepoint’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-81,000
Closed -$345K – 4026
2024
Q1 		$345K Buy
+81,000
New +$270K ﹤0.01% 3298

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Squarepoint's AQST Position: Q2 2026 in Review

Squarepoint reduced its Aquestive Therapeutics (AQST) stake by 72% in Q2 2026, selling an estimated $754K and leaving 70,422 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #3818.

Squarepoint first reported a position in AQST in Q4 2018 and has held it in 18 quarters since. The position peaked at $1.04M in Q1 2026. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Squarepoint held 70,422 shares of Aquestive Therapeutics worth $293K as of Q2 2026.
  • Squarepoint sold 179,060 Aquestive Therapeutics shares in Q2 2026, an estimated $754K.
  • Aquestive Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3818 holding.
  • Squarepoint first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 18 quarters since.
  • Squarepoint's Aquestive Therapeutics position peaked at $1.04M in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.